News

The technology will help in repairing a human blood vessel, as well as shows the development of new capillaries from a single vessel in response to proper biochemical

The company has engaged Rothschild as its independent financial advisor to assist Juniper and its Board of Directors in evaluating potential strategic alternatives. Juniper president and CEO Alicia

SAGE-217, administered as a single dose at either 30 or 45 mg, significantly improved sleep efficiency (SE), the primary endpoint of the trial, to a median of 85

The acquisition would improve Seattle Genetics' late-stage clinical pipeline with Tucatinib, an orally available and highly selective tyrosine kinase inhibitor (TKI) for patients with HER2-positive metastatic breast cancer As per the terms

CHMP has adopted a positive opinion recommending a label variation for Kyprolis (carfilzomib) to include updated overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial in

In addition, BridgeBio announced that it was launching new subsidiary QED Therapeutics to drive development of infigratinib with an initial financial commitment of $65 million. FGFR has been

The Houston-based company, which develops controllable cellular immunotherapies for cancers and orphan inherited blood disorders, said that the three cases of encephalopathy are thought to be possibly related

TAK-426 is a purified, inactivated, alum-adjuvanted and whole Zika virus vaccine candidate. Zika holds capacity to induce congenital Zika syndrome (CZS), including microcephaly and other congenital brain abnormalities,

The Phase I/II study (STELLAR-001) will evaluate the safety and efficacy of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in combination with Innate's investigational first-in-class anti-C5aR monoclonal antibody, IPH5401,